Incannex (IXHL) Healthcare announced that its Board of Directors has authorized a share repurchase program for up to $20M of the Company’s outstanding shares of common stock. The timing and amount of any repurchases will depend on market conditions, available capital resources, and other factors. Incannex Healthcare President and CEO Joel Latham commented, “The approval of this $20 million repurchase program reflects our confidence in the strength of our pipeline, the resilience of our strategy, and the opportunities ahead. We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs. This initiative allows us to act decisively, strengthen our capital management strategy, and potentially enhance long-term value creation for shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IXHL:
- Incannex Healthcare Reports Positive Phase 2 Trial Results
- Incannex announces patient-reported outcomes, efficacy data for IXHL-42X
- Incannex Healthcare Highlights Strong Cash Position and Strategy
- Incannex has no plans, requirement to fully utilized ATM in near term
- 3 Penny Stocks to Watch Now, 7/29/25